1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, is now being covered by UK based Edison Investment Research Ltd.

“We are happy to be working with Edison on providing equity research coverage. The team at Edison is highly regarded and professionally driving equity coverage in the pharma and biotech industry,” said Jeppe Øvelsen, Chief Executive Officer of SynAct Pharma.

Please see the Initiation Report on https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

Datum 2025-10-28, kl 10:50
Källa MFN
Bifogade filer
Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!